MedTrace Logo

Personalised Immunotherapy Platform

NCT06536257 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-09-18

No results posted yet for this study

Summary

This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice.

Conditions

Interventions

OTHER

Predictive model

Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.

Sponsors & Collaborators

  • Melanoma Institute Australia

    lead OTHER

Principal Investigators

  • James Wilmott, PhD · Melanoma Institute Australia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-08
Primary Completion
2027-06-01
Completion
2037-06-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06536257 on ClinicalTrials.gov